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Abstract
Background: Although retroviruses may invade host cells, a productive infection can be established only after the virus
counteracts inhibition from different types of host restriction factors. Fv1, APOBEC3G/F, TRIM5a, ZAP, and CD317 inhibit the
replication of different retroviruses by interfering with viral uncoating, reverse transcription, nuclear import, RNA stability,
and release. In humans, although APOBEC3G/3F and CD317 block HIV-1 replication, their antiviral activities are neutralized
by viral proteins Vif and Vpu. So far, no human gene has been found to effectively block wild type HIV-1 replication under
natural condition. Thus, identification of such a gene product would be of great medical importance for the development of
HIV therapies.
Method and Findings: In this study, we discovered a new type of host restriction against the wild type HIV-1 from a CD4/
CXCR4 double-positive human T cell line. We identified a CEM-derived cell line (CEM.NKR) that is highly resistant to
productive HIV-1 infection. Viral production was reduced by at least 1000-fold when compared to the other permissive
human T cell lines such as H9, A3.01, and CEM-T4. Importantly, this resistance was evident at extremely high multiplicity of
infection. Further analyses demonstrated that HIV-1 could finish the first round of replication in CEM.NKR cells, but the
released virions were poorly infectious. These virions could enter the target cells, but failed to initiate reverse transcription.
Notably, this restriction phenotype was also present in CEM.NKR and 293T heterokaryons.
Conclusions: These results clearly indicate that CEM.NKR cells express a HIV inhibitory gene(s). Further characterization of
this novel gene product(s) will reveal a new antiretroviral mechanism that directly inactivates wild type HIV-1.
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Introduction
Mammals have developed intracellular innate immunity that
affords them protection from retroviral infection. This immunity is
composed of different host antiviral genes, which are also called
restriction factors. So far, at least five different types of restriction
factors have been identified as important players for this
immunity: FV1, ZAP, APOBEC3G/F, TRIM5a, and CD317.
Fv1 is the first-discovered antiretroviral gene that restricts the
replication of murine leukemia virus (MuLV) [1]. It is a gag-like
gene from an endogenous retrovirus on mouse chromosome 4
[2,3]. It recognizes a single residue (R110/E110) on the incoming
MuLV capsid (CA) protein [4] and inhibits nuclear import of the
viral preintegration complex (PIC) [5,6]. Fv1 restriction is
saturable with a high multiplicity of viral infection (MOI). In
addition, during the functional cloning of antiviral genes from a rat
cDNA library, another MuLV inhibitory gene was identified [7].
This gene encodes a CCCH-type zinc finger protein, and is called
Zinc-finger antiviral protein (ZAP). ZAP can directly bind to viral
RNAs in the cytoplasm and degrade these targets [8]. It also
inhibits the replication of several viruses in the Alphavirus genus [9].
Although Fv1 is only expressed in mice, an Fv1-like block was
found in non-murine cells. When human and simian cells were
infected by the N-tropic MuLV or HIV-1, respectively, viral
replication was inhibited by a similar post-entry block [10–14].
The block is saturable and the same viral CA proteins are targeted.
This gene was identified as Trim5a, which belongs to the tripartite
motif (TRIM) family and blocks viral uncoating [15].
During the study of vif-deficient HIV-1 replication, a different type
of restriction was identified inso-called non-permissive cells [16]. This
restriction targets viral reverse transcription and APOBEC3G was
first identified to be responsible for this inhibition [17]. APOBEC3G
belongs to a small group of proteins in the cytidine deaminase family,
which is also known as APOBEC family [18]. This group of proteins
includes APOBEC3A, APOBEC3B, APOBEC3C, APOBEC3DE,
APOBEC3F, APOBEC3G, and APOBEC3H. The replication of
HIV-1 can be inhibited by APOBEC3B, APOBEC3DE, APO-
BEC3F, APOBEC3G, and A3POBEC3H [17,19–25]. APOBEC3G
shows the most powerful anti-HIV-1 activity [17]. Nevertheless,
HIV-1 is able to elude this defense mechanism and cause disease in
humans for two reasons. First, A3B and A3H are poorly expressed in
vivo [20,22,26,27]. Second, HIV-1 produces Vif, which binds to and
mediates the destruction of A3DE, A3F, and A3G in 26S
proteasomes via recruitment of the Cullin5 ubiquitin E3 ligase
[28,29]. Similarly, the viral protein, Vpu, was found to counter
another host restriction for HIV-1 in certain human cell lines that
PLoS ONE | www.plosone.org 1 July 2008 | Volume 3 | Issue 7 | e2796prevent virus fromrelease [30,31]. Thisrestriction gene was identified
as the cell surface protein CD317, which is an interferon a-inducible
gene named Tetherin [32]. Thus, no human gene has been identified
that effectively blocks the wild type HIV-1 replication under the
physiological condition.
CEM.NKR is a natural subclone of the human T lymphoblas-
toid cell line CEM. Like other cancer cell lines, CEM cells are very
sensitive to the natural killer (NK) cell-mediated lysis. However,
CEM.NKR was cloned from a subset of CEM cells that survived
from this killing [33]. Since CEM.NKR cells showed very low
affinity to NK cells, it was speculated that it lost an unknown cell
surface antigen(s) for NK cell recognition [33]. Later, it was found
that CEM.NKR does not express calnexin, a type I transmem-
brane protein identified as a major calcium binding protein of the
mammalian ER [34]. Calnexin binds to N-linked glycosylated
proteins and has a role in the retention of misfolded glycoproteins
in the ER [35]. However, genomic knock-in of a functional
calnexin gene into CEM.NKR did not increase NK cell sensitivity
[36]. Previously, an interaction between calnexin and the
uncleaved HIV-1 gp160 glycoprotein was detected [37]. Although
it was speculated that calnexin might function as a gp160
chaperone, no functional evidence was obtained [38,39].
Here, we report that although CEM.NKR expresses normal
levels of CD4 and CXCR4, it is highly resistant to a productive
HIV-1 replication. Further analysis indicated that this resistance is
not due to the lack of cellular factor such as calnexin, but the
presence of an unknown inhibitor(s).
Results
CEM.NKR is resistant to productive HIV-1 infection
Human cell lines that express CD4 and CXCR4 generally
should support productive T cell-tropic HIV-1 infection. To
discover novel HIV restriction factors, five human T cell lines were
chosen for HIV-1 infection experiments. A2.01, A3.01, CEM-T4,
and CEM.NKR are originally derived from CEM cells, and H9 is
originally from the Hut78 cell line. In addition, A2.01 is an A3.01
variant that has lost CD4 expression. FACS analysis revealed that
A3.01, CEM-T4, CEM-NKR, and H9 all expressed comparable
levels of CD4 and CXCR4, and A2.01 only expressed CXCR4
(Fig. 1A). Thus, it was assumed that CEM.NKR cells would
support a productive HIV-1 infection.
When these T cell lines were inoculated with T cell tropic HIV-
1, a robust viral replication was detected in A3.01, CEM-T4, and
H9 cells and no viral production was detected in A.201, which is
consist with viral receptor expression (Fig. 1B). Surprisingly, a very
marginal viral production was detected in CEM.NKR cells. After
eight days, the p24
Gag levels from CEM.NKR cell supernatant
were only 0.35 ng/ml, which was 2,860, 7,600, or 14,342-fold
lower than those from A3.01, H9, or CEM-T4 cells. We have tried
different T-tropic strains including NL and IIIB and obtained
similar results (not shown). Thus, we concluded that CEM.NKR is
resistant to productive infection.
To understand whether CEM.NKR cells express a Trim5a-like
inhibitory gene, cells were infected with increasing amounts of
HIV-1 to see whether this inhibition was saturable. A total of
1610
5 cells were inoculated with 100, 1000, or 10,000 ng of HIV-
1, which was equivalent to 50, 500, or 5,000 MOI, respectively,
and viral replication was observed for 8 days. As presented in
Fig. 2, we observed a similar variation in viral production among
four different cell lines on day 4, 6, and 8 post-infection. A2.01
cells were resistant to HIV-1 infection even at the highest MOI
and viral productions from A3.01 and H9 cells reached the
maximal levels at MOI 500 on day 8. In the case of CEM.NKR,
viral production was only increased marginally under these
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Figure 1. CEM.NKR is resistant to productive infection by HIV-1. A) CEM.NKR cell surface CD4 and CXCR4 expression determined by flow
cytometry and compared with the other indicated cell lines. B) HIV-1 infection kinetics. A total of 5610
5 of the indicated cells was infected with
100 ng HIV-1 (NL 4-3) and viral growth curves were determined by measuring p24
Gag in the supernatant. Results shown are one of three independent
experiments. The error bars for CEM.NKR represent standard deviation in these three independent experiments.
doi:10.1371/journal.pone.0002796.g001
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2 ng/ml on day 8. This level of production was at least 100 and
500-fold lower than those from H9 and A3.01 cells. These results
indicate that the resistance of CEM.NKR to HIV-1 was not
saturable, which is distinguishable from Trim5a restriction.
Stepwise analysis of HIV-1 life cycle in CEM.NKR cells
The resistance of CEM.NKR cells led us to investigate which step
in the virallife cycle was disrupted. Initially, we determinedwhether
HIV-1 could enter CEM.NKR cells and express viral proteins. We
used two previously described HIV-1 reporter viruses: pNL-Luc
and pNL-enCAT [40]. pNL-Luc contains a firefly luciferase (Luc)
gene in the Nef open reading frame (ORF) and the expression of
luciferase is from the 2 kb viral transcripts (Fig. 3A); pNL-enCAT
contains a chloramphenicol acetyl transferase (CAT) gene in the
gp120 ORF and the expression of CAT is from the 4 kb viral
transcripts (Fig. 3B). Both Luc and CAT-reporter viruses were
produced by transfection of 293T cells; the CAT-reporter virus was
pseudotyped with the vesicular stomatitis virus envelope glycopro-
tein (VSV-G) to provide a functional envelope. When cells were
infected with the Luc-reporter viruses, robust Luc activities were
detected in A3.01, CEM-T4, CEM.NKR, and H9 cells but not
A2.01 lacking viral receptors (Fig. 3A). This result demonstrated
that HIV-1 could efficiently enter CEM.NKR cells, and also make
the early gene products. Consistently, when cells were infected with
the CAT-reporter viruses, robust CAT activities were detected in
A2.01, A3.01, CEM-T4, CEM.NKR, and H9 cells but not in
A2.01(-), where A2.01 cells were infected by the same virus without
VSV-G pseudotyping (Fig. 3B). This result demonstrated that HIV-
1 could make the 4 kb transcripts and produce related proteins in
CEM.NKR cells as well as inA3.01, CEM-T4, H9,and A2.01 cells.
Next, we determined whether HIV-1 could make the 9 kb
transcripts where the Gag proteins were translated. Cells were
infected with env-deficient HIV-1 pseudotyped with VSV-G and
lysed 6 days post-infection to measure newly synthesized Gag
proteins. As presented in Fig. 3C, comparable levels of Gag
proteins were detected in A2.01, A3.01, CEM-T4, CEM.NKR,
and H9 cells, which were significantly higher than those in A2.01
cells infected by the same virus without VSV-G pseudotyping.
This result demonstrated that HIV-1 could make Gag proteins in
CEM.NKR cells, suggesting that the 9 kb viral transcripts are
normally produced.
Finally, we determined whether viral particles were released
from these cells. As in Fig. 3C, culture supernatants were collected
2 or 6 days post-infection and levels of extracellular Gag protein
were determined by ELISA (Fig. 3D). The Gag protein levels from
CEM.NKR cell culture increased 3-fold, whereas a 5, 7, 3, or 2-
fold increase was detected from A2.01, A3.01, CEM-T4, or H9
cell culture, respectively. No increase was detected from A2.01 cell
culture inoculated with the same virus without VSV-G pseudotyp-
ing, and their values were significantly lower than those samples
infected by VSV-G pseudotyped viruses. This result demonstrated
that HIV-1 particles are assembled and released from CEM.NKR
cells. Thus, there is no apparent defect in HIV-1 replication
during the first cycle in CEM.NKR cells.
Characterization of CEM.NKR released HIV-1
To know whether a block might occur during the next round of
replication, we measured viral infectivity. To increase viral
production from CEM.NKR cells, viruses were pseudotyped with
VSV-G before infection. VSV-G pseudotyped HIV-1 viruses were
first created from 293T cells and used to infect CEM.NKR, H9,
CEM-T4, A3.01, and A2.01 cells. Viruses were collected from
these cell cultures 24 hours post-infection. After normalized by
p24
Gag, the same amounts of viruses were collected to infect TZM-
bl cells, a HIV-reporter cell line expressing the Luc gene under
HIV LTR control. As presented in Fig. 4A, the infectivity of
virions produced from CEM.NKR cells was at least 15-fold lower
than that from H9, CEM-T4, A3.01, and A2.01 cells. It should be
noted that this decrease was underestimated because TZM-bI cells
produce certain levels of luciferase activity even without viral
infection. Thus, CEM.NKR released virions are poorly infectious,
which explains why productive viral infection could not be
established.
To understand why virions are not infectious, we determined
whether these virions lost any of important viral components. To
prepare high quantity purified virions, CEM.NKR cells were
infected with HIV-1 carrying a neomycin-resistant marker and a
persistently infected cell line was created by G418 selection.
Virions were then purified from culture supernatant by ultracen-
trifugation and viral proteins were determined by Western
blotting. As a control, virions were also produced from 293T
cells. As presented in Fig. 4B, viral reverse transcriptase (p66
RT),
integrase (p32
IN), capsid (p24
CA), matrix (p17
MA), gp120, and
gp41 proteins were all detected in virions from CEM.NKR cells,
indicating that viral Gag, Pol, and Env proteins were properly
expressed, processed, assembled, and incorporated into virions.
The migration of gp120 proteins from CEM.NKR cells in SDS gel
was slightly slower than that from 293T cells, which might reflect a
difference in protein glycosylation in these cells.
Viral input (p24Gag ng/ml)
Day 4 Day 6 Day 8
0.01
0.1
1
10
100
1000
10000
100 1,000 10,000
A2.01
CEM.NKR
H9
A3.01
0.01
0.1
1
10
100
1000
10000
100 1,000 10,000
0.01
0.1
1
10
100
1000
10000
100 1,000 10,000
Figure 2. The resistance factor in CEM.NKR is not saturable with HIV-1 virus. Cells were infected with increasing amounts of HIV-1 followed
by determination of supernatant p24
Gag using ELISA at four, six, and eight days.
doi:10.1371/journal.pone.0002796.g002
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and 293T cells were incubated with TZM-bl cells at 37 uC. After
0, 0.5, and 3 hours, cells were washed extensively and trypsinized
to remove viruses that were only attached to the cell surface. Cells
were then lysed and levels of intracellular p24
CA were determined
by Western blotting. A time-dependent increase of intracellular
p24
CA proteins was observed in cells infected with both viruses,
but the levels of increase in cells infected with 293T-derived viruses
were higher than those infected with CEM.NKR-derived viruses
(Fig. 4C). Thus, although we could conclude that virions from
CEM.NKR cells were able to enter the target cell, a minor defect
in viral entry could not be completely excluded.
Finally, we determined whether viruses could initiate reverse
transcription inthe targetcells.CEM-SS cells wereinfected withthe
same amounts of viruses produced from either CEM.NKR or 293T
cells. After 2, 6, or 18 hours of infection, cellular DNAs were
extracted and viral early or late reverse transcription (RT) products
were quantitated by Real-time PCR (Fig. 4D). The levels of both
early and late RT products in cells infected with virions from
CEM.NKR were extremely low and decreased in a time-dependent
manner. In contrast, levels of both viral RT products in cells
infected with virions from 293T were very high and increased in a
time-dependent manner. The differences in the levels of viral RT
productsin cellsinfected with thesetwo differentvirusescould reach
10
3 to 10
4-fold after 18 hours of infection. Since such huge
differences could not be simply explained by the difference in entry
between these two viruses, we concluded that virions from
CEM.NKRcellsfail toinitiatereversetranscription,whichbecomes
a major post-entry block to the virus in the target cells.
CEM.NKR cells express a HIV-1 inhibitor(s)
We proposed two hypotheses to explain why viruses from
CEM.NKR cells are not infectious: 1) CEM.NKR cells lack
cofactor(s) essential for HIV-1 replication; and 2) CEM.NKR cells
expresses dominant inhibitor(s) that blocks HIV-1 replication. A
trans-complementation assay that detects infectious viral particles
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Figure 3. Single-round HIV-1 replication in human T cell lines. A) Expression of viral protein from multiply spliced RNA species. The simple
reference diagram at the top of the figure indicates the position of the reporter gene in the viral genome. The indicated cell lines were infected with
pNL-Luc reporter viruses. Twenty-four hours later, intracellular luciferase activity was measured. B) Expression of viral protein from singly spliced RNA
species. The indicated cell lines were infected with VSV-G pseudotyped pNL-enCAT reporter viruses followed by intracellular CAT activity assay
24 hours later. A2.01(-) served as a negative control where A2.01 cells were infected by the same virus without VSV-G pseudotying. C) Expression of
viral protein from un-spliced RNA species. The indicated cell lines were infected by env-deficient HIV-1 pseudotyed with VSV-G. Six days later the
levels of intracellular Gag protein were determined by ELISA. A2.01(-) served as a negative control where A2.01 cells were infected by the same virus
without VSV-G pseudotying. D) Levels of viral release. The infection experiment was performed as in C) and levels of viral release were determined by
p24
Gag ELISA. Error bars in these experiments represent standard deviations in three independent experiments.
doi:10.1371/journal.pone.0002796.g003
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Figure 4. Characterization of CEM.NKR-released virions. A) Viral infectivity assay. The indicated T cells were infected with HIV-1 pseudotyped
by VSV-G and equal amounts of viruses as measured by p24
Gag were collected to infect TZM-bl cells. Viral infectivity was determined by measuring
cellular luciferase activity twenty-four hours’ later. B) Viral protein expressions. Proteins from virions from HIV-infected CEM.NKR cells or transfected
293T cells were analyzed by Western blotting using human anti-HIV polyclonal, mouse anti-gp41 monoclonal, and mouse anti-gp120 monoclonal
antibodies. C) Viral entry assay. Viruses purified in B) were incubated with TZM-bl cells for 0, 0.5, and 3 hours followed by Western blotting analysis of
intracellular viral p24
Gag. D) Real-time PCR analysis of viral reverse transcripts. Viruses purified in B) were used to infect CEM-SS cells and cellular DNAs
were extracted at the indicated time points. Levels of the early (left panel) or late reverse transcripts (right panel) were determined by real-time PCR.
The position of the early and late primer pairs is indicated by arrows above the panels. E) A schematic description of the transient trans-
complementation assay via heterokaryon formation. T cells were infected with env-defective HIV-1 virus pseudotyped with VSV-G and 293T cells
transfected with Env-expressing vector pNLDGag. Cells were then co-cultured for heterokaryon formation and infectious particles were detected by
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Heterokaryons were formed by HIV-1 Env and CD4/CXCR4
mediated cell fusion of non-permissive CEM.NKR cells and
permissive 293T cells. Infectious viral particles were detected by
infection of TZM-bI cells. If viruses produced from heterokarons are
infectious, CEM.NKR cells should lack cofactor(s); otherwise,
CEM.NKR cells should express inhibitor(s). To ensure that particles
are produced exclusively from heterokaryons, viral proteins were
expressed separately from these two cell types. In addition, since
CEM.NKR lacks calnexin that might have unknown function for
viral gp160, we chose to express gp160 in 293T cells and the env-
deficient viral particles were produced from CEM.NKR (Fig. 4E).
Initial control experiments were performed to make sure this
experiment worked as desired. As presented in Fig. 4F, no infectious
particles were recovered from 293T cells expressing either Env
protein or producing env-deficient viral particles; or from co-cultures
between 293T and A2.01 cells. In sharp contrast, when A2.01 cells
were replaced with H9, A3.01, CEM-T4, CEM.SS, and Hut78
cells, high titers of infectious particles could be recovered from the
co-culture, indicating successful heterokaryon formations between
293T and these T cells. Notably, when Env-expressing 293T cells
were co-cultured with CEM.NKR cells producing env-deficient
viruses, no infectious particles were detected. It is unlikely that
CEM.NKR failed to fuse with 293T cells because CEM.NKR cells
express high levels of CD4 and CXCR4 (Fig. 1A), which is
functional for viral entry (Fig. 4C). Thus, the only possibility is that
CEM.NKR cells express an inhibitor(s) that potently block HIV-1
replication. This result also excludes the responsibility of calnexin
for HIV restriction in CEM.NKR cells.
CEM.NKR-CCR5 and CEM.NKR-CCR5-Luc cell lines are also
resistant to productive HIV-1 infection
Two additional cell lines have been generated from CEM.NKR.
The first is CEM.NKR-CCR5 that was created by stable
transduction of CEM.NKR with a CCR5-expressing vector
[43]. The second is CEM.NKR-CCR5-Luc that was created by
stable transfection of CEM.NKR-CCR5 cells with a HIV-2 LTR-
Luc expression vector [44]. These two cell lines were previously
shown to express similar levels of CD4 and CXCR4 levels when
compared to the parent cell line CEM.NKR [44]. To test whether
these two cell lines retained the HIV-resistance phenotype, they
were infected with HIV-1 strain NL4-3. As shown in Fig. 5A,
CEM.NKR, CEM.NKR-CCR5, and CEM.NKR-CCR5-Luc
were equally resistant to productive HIV-1 infection, whereas
the CEM-T4 cell line was highly permissive for HIV-1 infection.
To determine whether HIV-1 could enter CEM.NKR cells, we
measured intracellular luciferase activity in CEM.NKR-CCR5-
Luc cells. Before infection we found only a background level of
luciferase activity at around 1,000 cpm. This activity increased at
least 30-fold upon viral infection. Cells without the luciferase gene
(CEM-T4, CEM.NKR, and CEM.NKR-CCR5) were negative
(Fig. 5B). Thus, we conclude that HIV-1 can enter CEM.NKR
cells. Together, these results are consistent with the conclusion that
HIV-1 resistance in CEM.NKR cells is due to a post-entry block
during the 2
nd round of viral infection.
Discussion
We have demonstrated that CEM-NKR cells express a novel
restriction factor(s) that poses a major post-entry block to HIV-1.
Three pieces of evidence indicate that this restriction might not be
caused by an entry block due to the lack of calnexin. First, the fact
that gp120 and gp41 were both detected from virions released
from CEM.NKR (Fig. 4B) confirms that gp160 is folded and
processed correctly in the ER. Second, virus could enter the target
cell (Fig. 4C). Third, the trans-complementation of functional
gp160 proteins from 293T cells did not release virus from this
block (Fig. 4F). However, it should be noted that our data cannot
completely rule out a possible entry block that may play a minor
infection of TZM-bI cells. F) Infectivity of HIV-1 produced from heterokaryons. The Env-expressing 293T cells were co-cultured with indicated T cells
producing env-defective HIV-1. After 48 hours, viral infectivity from the co-culture was determined in TZM-bl cells. Results shown here were from one
of three independent experiments.
doi:10.1371/journal.pone.0002796.g004
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Figure 5. HIV resistance in two other CEM.NKR-derived cell lines. A) HIV-1 infection kinetics. A total of 5610
5 CEM-T4, CEM.NKR, CEM.NKR-
CCR5, or CEM.NKR-CCR5-Luc cells was infected with 100 ng HIV-1 (NL 4-3) and viral infection was determined by measuring p24
Gag in the supernatant
over 6 days. B) Cellular luciferase activity. These cells were infected with HIV-1 as in A). Three days later, cells were lysed and cellular luciferase activity
was determined.
doi:10.1371/journal.pone.0002796.g005
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APOBEC3H can inactivate wild type HIV-1, we failed to detect
their mRNAs from CEM.NKR (data not shown). Moreover, since
this inhibition is not saturable (Fig. 2), it does not have the
properties of a Trim5a-like block. Nevertheless, we cannot
completely exclude the antiviral activity from the other Trim
family members in CEM.NKR cells [45].
Initially, we were very surprised by that CEM.NKR cells were
highly resistant to HIV-1 replication because two CEM.NKR-
derived cell lines, CEM.NKR-CCR5 and CEM.NKR-CCR5-
Luc, were developed to study HIV-1 infection [43,44]. These cell
lines are available through NIH AIDS Research and Reference
Reagent Program. Our results confirmed that HIV-1 can enter
these cells, but they are equally resistant to productive HIV-1
infection. Interestingly, although CEM.NKR-CCR5 is recom-
mended for infection with primary HIV isolates and neutralization
assays, it is indeed acknowledged in the data sheet that this cell line
does not secrete infectious virus. Moreover, it is not surprising that
CEM.NKR-CCR5-Luc can be used as HIV-indicator cell because
we also showed that CEM.NKR is infectable with HIV-1.
Although this cell line was reported to be permissive for viral
replication, the original report shows a peak of viral production of
only about 10 ng/ml [44]. This value is just slight higher than that
we detected in Fig. 2. Although CEM-NKR cells can be infected
with HIV-1, they do not effectively produce infectious particles.
Taken together, these results have permitted the identification of a
new type of HIV-1 restriction factor(s) in CEM.NKR cells. Further
elucidation of the nature of this restriction factor will uncover a
novel antiretroviral mechanism that effectively inhibits wild type
HIV-1 replication.
Materials and Methods
Plasmids, cell lines, and viruses
HIV-1 proviral constructs pNL4-3, pNL-Luc, and pNL-enCAT
were described before [25,40]. pNL-Neo was created by replacing
the firefly luciferase in pNL-Luc with the neomycin-resistant gene
by NotI/XhoI double digestion. pNLDGag and pNLDEnv were
created by SphI/AgeI double or NheI single digestion of pNL4-3
followed by large Klenow fragment treatment before T4 ligation.
The NheI site is still active in pNLDEnv although the env gene was
inactivated by a frame-shift.
The HIV indicator cell line TZM-bI and human T cell lines
HUT 78, H9, PM1, CEM-SS, CEM.NKR, CEM.NKR-CCR5,
CEM.NKR-CCR5-Luc, A3.01, and A2.01 were from NIH AIDS
Research and Reference Reagent Program. T cells were cultured
in RPMI 1640 with 10% fetal bovine serum (HyClone). 293T and
TZM-bI were cultured in DMEM with 10% bovine calf serum
(HyClone).
Viruses were produced from 293T cells by the standard calcium
phosphate transfection of the proviral constructs. HIV-1 IIIB were
obtained from NIH AIDS Research and Reference Reagent
Program and propagated in H9 cells.
Antibodies
The following antibodies were obtained through the AIDS
Research and Reference Reagent Program: human anti-HIV
immunoglobulin (#3957) from NABI, HIV-1 IIIB gp41 hybrid-
oma (#526) from George Lewis, HIV-1 IIIB gp120 hybridoma
(#902) from Bruce Chesebro, HIV-1 p24 hybridoma from Bruce
Chesebro and Hardy Chen. Other antibodies used included a
polyclonal rabbit anti-actin antibody (C-11) (Santa Cruz Biotech-
nology), PE-conjugated mouse anti-human CXCR4 and FITC-
conjugated mouse anti-human CD4 (BD Biosciences), and HRP-
conjugated anti-rabbit, human, or mouse IgG secondary antibod-
ies (Pierce). Detection of the HRP-conjugated antibody was
performed using Supersignal Wetpico Chemiluminescence Sub-
strate kit (PIERCE).
HIV-1 infection of human T cell lines
1610
5 cells were incubated with 100 ng wild type HIV viruses
at 37uC for three hours. After removal of the inocula followed by
three extensive washings, cells were cultured in 24-well plates for
eight days. Culture supernatants were then collected daily for
measurement of p24
Gag by ELISA.
Real-time PCR measurement of viral reverse transcripts
5610
6 CEM-SS cells were infected with HIV-1 equivalent to
200 ng p24
CA and cellular DNAs were extracted 2, 6, and
18 hours after infection using the DNeasy kit (QIAGEN). After
digestion with DpnI, viral reverse transcripts were determined by
real-time PCR using TaqManH Gene Expression Master Mix kit
(Applied Biosystems). The early reverse transcripts (strong stop)
were amplified by previously described primers oHC64 and
oHC65 and quantitated by a fluorescence labeled probe oHC66
[46]. The late reverse transcripts were amplified by previously
described primers MH531 and MH532 and the labeled probe was
LRT-P [47]. Reactions were analyzed by the ABI 7900HT
(Applied Biosystems).
CAT assay
Chloramphenicol acetyl transferase (CAT) activity was deter-
mined as before [48]. Briefly, cells were lysed in 0.25 M Tris-HCl
at pH 7.5 containing 0.1% Triton X-100. Lysates were incubated
at 65 uC for 5 min to inactivate the endogenous CAT enzyme.
Nuclei were then removed from the lysates by centrifugation.
Cleared lysates (100 ml) were mixed with CAT reaction solution
(50 ml) containing 0.5 ml acetyl-conenzyme A (4.90 Ci mmol
21),
41.5 mg chloramphenicol and 5 ml 0.25M Tris-HCl at pH 7.5.
Finally, 3 ml Econoflour (Packard Bioscience, Netherland) was
added to the reaction before scintillation counting. Activity was
expressed as the slope of the enzyme activity.
Heterokaryon formation
A previously established protocol was adopted [41,42]. Briefly,
293T cells were seeded in six-well plates at 8610
5/well in 2 ml
medium. Twelve hours later, cells were transfected with 6 mgo f
HIV Env expression vector pNLDGag and washed with PBS four
hours’ later. Simultaneously, 8610
5 T cells were infected with
500 ng of VSV-pseudotyped Env-defective HIV-1 from
pNLDEnv-transfected 293T cells at 37uC for three hours. After
removal of the inocula and extensive washing, infected T cells
were added to the Env-expressing 293T cell culture. After
48 hours, supernatants from these co-cultures were collected to
infect TZM-bI cells. Viral infectivity was finally determined by
measuring cellular luciferase activities after another 48 hours.
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